Navigation Links
Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Date:4/30/2009

TAMPA, Fla., April 30 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that eight presentations related to the Company's products, pipeline and research will be presented at the 2009 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO)

These presentations include data related to Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, fenretinide, and retinal research programs from the Sirion San Diego, CA based drug discovery laboratory.

Durezol (difluprednate ophthalmic emulsion) 0.05% was approved by the U.S. Food & Drug Administration (FDA) after an expedited review in June 2008 for the treatment of post-operative inflammation and pain associated with ocular surgery. A supplemental New Drug Application (sNDA) was filed in December 2008 seeking an approval for Durezol as a treatment for endogenous anterior uveitis based partially on a head to head comparison to Pred Forte(R). The application was accepted in February 2009 by the agency and is under review.

Fenretinide is currently being evaluated in an ongoing phase II clinical trial in the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). The trial is a two year multicenter, randomized, double-masked, placebo controlled, dose-comparison in over 225 patients at 30 sites in the United States. A summary of the preliminary results of a planned interim analysis of this study was provided in a press release made by Sirion on April 15th, 2009. The ARVO presentations on fenretinide contain a more detailed analysis of the data obtained from the interim analysis.

Identified below are the presentations scheduled for the upcoming ARVO meeting.

Dose Uniformity of Prednisolone Acetate Ophthalmic Suspensions Compared to Durezol (difluprednate ophthalmic emulsion) 0.05%

Session Date/Start Time: Monday May 4, 8:30-10:15 am

Posterboard Number: A351 - Program Number: 1461

Durezol Compared to Pred Forte(R) in the Treatment of Endogenous Anterior Uveitis

Session Date/Start Time: Tuesday May 5, 8:30-10:15 am

Posterboard Number: D1106 - Program Number: 2697

Sirion Therapeutics Poster Presentations Featuring Fenretinide

A Phase II Multicenter, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects with Age-Related Macular Degeneration: Preliminary Demographic Data and Reasons for Screen Failure

Session Date/Start Time: Wednesday May 6, 3:45-5:30 pm

Posterboard Number: A451 - Program Number: 4918

A Phase II, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects with Age-Related Macular Degeneration: Baseline Lesion Size, Characteristics, and Preliminary Progression Data

Session Date/Start Time: Wednesday May 6, 3:45-5:30 pm

Posterboard Number: A452 - Program Number: 4919

Sirion Therapeutics Poster Presentations Featuring Retinal Research

Accumulation of Toxic Retinal Fluorophores in Various Degenerative Retinal Diseases

Session Date/Start Time: Wednesday May 6, 8:30-10:15 am

Posterboard Number: A444 - Program Number: 4188

Characterization of Fluorophores in the Diseased Retinal Pigment Epithelium

Session Date/Start Time: Wednesday May 6, 8:30-10:15 am

Posterboard Number: A427 - Program Number: 4171

Anti-Angiogenic Properties of N-(4-hydroxyphenyl) Retinamide in Ocular Tissue

Session Date/Start Time: Sunday May 3, 8:30-10:15 am

Posterboard Number: A43 - Program Number: 56

Fenretinide Ameliorates Retinal Pathology in the Ins2Akita Diabetic Mouse

Session Date/Start Time: Sunday May 3, 8:30-10:15 am

Posterboard Number: A42 - Program Number: 55

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development, and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion Therapeutic, Inc. has a diverse product portfolio which includes products that address ocular diseases and conditions including uveitis, herpetic keratitis, dry eye, and geographic atrophy associated with dry AMD. For more information, please visit http://www.siriontherapeutics.com.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
2. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
(Date:2/11/2016)... OAKLAND, Calif. , Feb. 11, 2016  Walgreens ... stores across 39 states and Washington, D.C. ... in a move that was commended by shareholder advocacy organization ... President at As You Sow. "Many people hold on to ... options, which can have tragic consequences." --> ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released Infusion ... technology should be used to ensure patient safety when placing an IV catheter. ... mandate the use of vein visualization technology in patients with difficult venous access ...
(Date:2/12/2016)... , ... February 12, 2016 , ... According to an ... are beginning to account for a significant portion of hernia repairs throughout the United ... the Beverly Hills Hernia Center notes that this trend has not only been expected, ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. ... , As Winston Churchill said, “Those who don’t learn from history are doomed to repeat ... when they come knocking this year. But that takes time. , Take a close ...
(Date:2/12/2016)... ... 12, 2016 , ... T.E.N., a technology and information security ... Southeast Awards 2016. Finalists and winners of the ISE® Awards for both Executive ... Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally ... a charity drive that will raise funds earmarked to purchase computers and software for ... School. , “My school is in a low-income area and has more than 60 ...
Breaking Medicine News(10 mins):